

Stefania Mantovani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5212648/publications.pdf>

Version: 2024-02-01

62
papers

4,474
citations

159585
30
h-index

133252
59
g-index

67
all docs

67
docs citations

67
times ranked

9521
citing authors

#	ARTICLE	IF	CITATIONS
1	Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity. Human Genetics, 2022, 141, 147-173.	3.8	22
2	The polymorphism L412F in <i>TLR3</i> inhibits autophagy and is a marker of severe COVID-19 in males. Autophagy, 2022, 18, 1662-1672.	9.1	25
3	MICA/B-targeted antibody promotes NK cell-driven tumor immunity in patients with intrahepatic cholangiocarcinoma. Oncoimmunology, 2022, 11, 2035919.	4.6	13
4	Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients. Genes and Immunity, 2022, 23, 51-56.	4.1	41
5	Adaptive Natural Killer Cell Functional Recovery in Hepatitis C Virus Cured Patients. Hepatology, 2021, 73, 79-90.	7.3	15
6	Unique immunological profile in patients with COVID-19. Cellular and Molecular Immunology, 2021, 18, 604-612.	10.5	181
7	Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research. European Journal of Human Genetics, 2021, 29, 745-759.	2.8	35
8	EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. International Journal of Infectious Diseases, 2021, 104, 315-319.	3.3	66
9	Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males. EBioMedicine, 2021, 65, 103246.	6.1	52
10	Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study. ELife, 2021, 10, .	6.0	145
11	Protective Role of a TMPRSS2 Variant on Severe COVID-19 Outcome in Young Males and Elderly Women. Genes, 2021, 12, 596.	2.4	39
12	C9orf72 Intermediate Repeats Confer Genetic Risk for Severe COVID-19 Pneumonia Independently of Age. International Journal of Molecular Sciences, 2021, 22, 6991.	4.1	12
13	A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C. Journal of Viral Hepatitis, 2021, 28, 1443-1451.	2.0	1
14	Mapping the human genetic architecture of COVID-19. Nature, 2021, 600, 472-477.	27.8	640
15	Genetic mechanisms of critical illness in COVID-19. Nature, 2021, 591, 92-98.	27.8	1,014
16	High Frequencies of Functional Virus-Specific CD4+ T Cells in SARS-CoV-2 Subjects With Olfactory and Taste Disorders. Frontiers in Immunology, 2021, 12, 748881.	4.8	11
17	ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population. European Journal of Human Genetics, 2020, 28, 1602-1614.	2.8	208
18	An Anti-MICA/B Antibody and IL-15 Rescue Altered NKG2D-Dependent NK Cell Responses in Hepatocellular Carcinoma. Cancers, 2020, 12, 3583.	3.7	16

#	ARTICLE	IF	CITATIONS
19	Expansion of atypical memory B cells is a prominent feature of COVID-19. Cellular and Molecular Immunology, 2020, 17, 1101-1103.	10.5	76
20	Detection of the SARS-CoV-2 in different biologic specimens from positive patients with COVID-19, in Northern Italy. Pediatric Allergy and Immunology, 2020, 31, 72-74.	2.6	4
21	Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COVID19 REgistry (SMACORE). Microorganisms, 2020, 8, 695.	3.6	186
22	Emergency Department and Out-of-Hospital Emergency System (112-AREU 118) integrated response to Coronavirus Disease 2019 in a Northern Italy centre. Internal and Emergency Medicine, 2020, 15, 825-833.	2.0	50
23	SARS Cov-2 infection in a renal-transplanted patient: A case report. American Journal of Transplantation, 2020, 20, 1882-1884.	4.7	76
24	Natural Killer Cell Responses in Hepatocellular Carcinoma: Implications for Novel Immunotherapeutic Approaches. Cancers, 2020, 12, 926.	3.7	42
25	Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit. Clinical Microbiology and Infection, 2020, 26, 1094.e1-1094.e5.	6.0	121
26	Clinical and molecular characterization of COVID-19 hospitalized patients. PLoS ONE, 2020, 15, e0242534.	2.5	25
27	Human Monoclonal Antibodies as Adjuvant Treatment of Chronic Hepatitis B Virus Infection. Frontiers in Immunology, 2019, 10, 2290.	4.8	5
28	Decreased interferon- γ production by NK cells from KIR haplotype B carriers in hepatitis C virus infection. Liver International, 2019, 39, 1237-1245.	3.9	3
29	THU-482-A human anti-MICA/B antibody boost NK cell responses in hepatocellular carcinoma. Journal of Hepatology, 2019, 70, e373.	3.7	1
30	Deficient Natural Killer Cell Nkp30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma. Hepatology, 2019, 69, 1165-1179.	7.3	48
31	Altered natural killer cell cytokine profile in type 2 autoimmune hepatitis. Clinical Immunology, 2018, 188, 31-37.	3.2	8
32	Defective Nkp30-mediated function in hepatocellular carcinoma-infiltrating NK cells. Journal of Hepatology, 2018, 68, S679-S680.	3.7	2
33	Defective DNAM-1 mediated cytotoxicity in NK cells infiltrating hepatocellular carcinoma. Journal of Hepatology, 2018, 68, S667.	3.7	0
34	Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity. Journal of Hepatology, 2017, 66, 1130-1137.	3.7	32
35	Monocytes inhibit hepatitis C virus-induced TRAIL expression on CD56bright NK cells. Journal of Hepatology, 2017, 67, 1148-1156.	3.7	20
36	Hepatitis C virus inhibits CD4 T cell function via binding to Toll-like receptor 7. Antiviral Research, 2017, 137, 108-111.	4.1	16

#	ARTICLE	IF	CITATIONS
37	Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection. <i>Gut</i> , 2016, 65, 1998-2006.	12.1	50
38	<scp>NK</scp>p30 isoforms in patients with chronic hepatitis C virus infection. <i>Immunology</i> , 2015, 146, 234-242.	4.4	23
39	Skewed B cells in chronic hepatitis C virus infection maintain their ability to respond to virus-induced activation. <i>Journal of Viral Hepatitis</i> , 2015, 22, 391-398.	2.0	34
40	FcγRIIIa shedding from NK cells does not impair antibody-dependent cellular cytotoxicity in chronic HCV infection. <i>Digestive and Liver Disease</i> , 2014, 46, e49.	0.9	0
41	P124 MATRIX METALLOPROTEINASE (MMP)-DEPENDENT SHEDDING REDUCES NK CELL FcγRIIIa EXPRESSION IN CHRONIC HCV INFECTION WITHOUT AFFECTING THE EFFICIENCY OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY. <i>Journal of Hepatology</i> , 2014, 60, S107.	3.7	0
42	Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. <i>Journal of Hepatology</i> , 2013, 59, 38-44.	3.7	52
43	Natural killer cell functional dichotomy: a feature of chronic viral hepatitis?. <i>Frontiers in Immunology</i> , 2012, 3, 351.	4.8	29
44	Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection. <i>Hepatology</i> , 2012, 56, 841-849.	7.3	94
45	Amyotrophic Lateral Sclerosis Multiprotein Biomarkers in Peripheral Blood Mononuclear Cells. <i>PLoS ONE</i> , 2011, 6, e25545.	2.5	123
46	Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: Clinical and biological results from a prospective multicenter study. <i>Muscle and Nerve</i> , 2011, 43, 189-195.	2.2	64
47	Nitroproteomics of Peripheral Blood Mononuclear Cells from Patients and a Rat Model of ALS. <i>Antioxidants and Redox Signaling</i> , 2009, 11, 1559-1567.	5.4	35
48	Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. <i>Journal of Neuroimmunology</i> , 2009, 210, 73-79.	2.3	156
49	An in vitro model of T cell receptor revision in mature human CD8+ T cells. <i>Molecular Immunology</i> , 2008, 45, 328-337.	2.2	17
50	Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?. <i>Pigment Cell & Melanoma Research</i> , 2005, 18, 234-242.	3.6	41
51	Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo. <i>European Journal of Immunology</i> , 2005, 35, 3153-3162.	2.9	32
52	Transfer of efficient anti-melanocyte T cells from vitiligo donors to melanoma patients as a novel immunotherapeutical strategy. <i>Journal of Autoimmune Diseases</i> , 2005, 2, 7.	1.0	4
53	Molecular and Functional Bases of Self-Antigen Recognition in Long-Term Persistent Melanocyte-Specific CD8+ T Cells in One Vitiligo Patient. <i>Journal of Investigative Dermatology</i> , 2003, 121, 308-314.	0.7	28
54	Analysis of Secondary V(D)J Rearrangements in Mature, Peripheral T Cells of Ataxia-Telangiectasia Heterozygotes. <i>Laboratory Investigation</i> , 2003, 83, 1467-1475.	3.7	16

#	ARTICLE	IF	CITATIONS
55	Dominant TCR-Î± Requirements for a Self Antigen Recognition in Humans. Journal of Immunology, 2002, 169, 6253-6260.	0.8	40
56	Human CD8 coâ€“receptor is strictly involved in MHCâ€“peptide tetramerâ€“TCR binding and T cell activation. International Immunology, 2002, 14, 39-44.	4.0	41
57	Cytotoxic T-lymphocyte responses in melanoma through in vitro stimulation with the Melan-A peptide analogue A27L: a qualitative analysis. Melanoma Research, 2002, 12, 491-498.	1.2	7
58	Specific Cytotoxic T Lymphocyte Responses Against Melan-A/MART1, Tyrosinase and Gp100 in Vitiligo by the Use of Major Histocompatibility Complex/Peptide Tetramers: the Role of Cellular Immunity in the Etiopathogenesis of Vitiligo. Journal of Investigative Dermatology, 2001, 117, 326-332.	0.7	173
59	Kinetics of GATA-3 gene expression in early polarizing and committed human T cells. Immunology, 2001, 102, 123-130.	4.4	36
60	Diverse expansion potential and heterogeneous avidity in tumor-associated antigen-specific T lymphocytes from primary melanoma patients. European Journal of Immunology, 2001, 31, 412-420.	2.9	38
61	Increased frequency of RAG-expressing, CD4+CD3low peripheral T lymphocytes in patients with defective responses to DNA damage. European Journal of Immunology, 2000, 30, 1520-1525.	2.9	24
62	Cutting Edge: Recombinase-Activating Gene Expression and V(D)J Recombination in CD4+CD3low Mature T Lymphocytes. Journal of Immunology, 2000, 164, 3455-3459.	0.8	40